Migraine Focus STS101 nasal powder targets acute migraine, creating opportunities to engage neurology clinics, headache centers, and specialty pharmacies with a differentiated early treatment option.

Outsourcing Needs As a small, clinical-stage company, Satsuma is well positioned to partner with CROs and CMOs for clinical development, manufacturing, packaging, and nasal delivery device needs.

Strategic Partnerships Historical acquisition by SNBL and ongoing abstracts at major headache symposia indicate readiness for licensing, co-development, or out-licensing discussions to accelerate STS101's path to market.

Market Access Active participation in industry conferences and KOL engagement presents opportunities to shape payer strategies, form advisory relationships, and explore early access programs for STS101.

Growth Opportunities A mid-stage revenue profile and small team suggest openness to collaboration or licensing with larger pharma to scale commercialization and manufacturing capabilities.